Henlius Files Chinese Application For Perjeta Biosimilar
The Application Doubles Down On Positive Data Announced This Year
A few months after a positive Phase III trial readout, Henlius has filed an application for its Organon-partnered Perjeta biosimilar in its domestic Chinese market.
